Why 2026 is dubbed the inaugural year for alternative postprandial glycemic management ingredients

For a brand developing a meal-time metabolic health concept, the value of a DNJ ingredient depends on more than its purity percentage. The team needs to understand what the material is, where its biological activity is relevant, how closely the published research matches the proposed formulation, and what documentation supports commercial development.

DNJ, short for 1-deoxynojirimycin, is an iminosugar studied for its interaction with intestinal carbohydrate-digesting enzymes. That gives formulators a specific scientific starting point. Turning that starting point into a credible product requires decisions about ingredient form, actual DNJ content, release, tolerability, and quality control. 

What DNJ means on an ingredient specification

Three descriptions often appear in supplier discussions: DNJ, DNJ-enriched mulberry leaf extract, and DNJ hydrochloride. They describe related materials, but they are not interchangeable specifications.

DNJ identifies the molecule. A standardized mulberry extract contains DNJ within a broader ingredient matrix; its specification should state the amount of DNJ rather than only the total extract weight. DNJ hydrochloride, often written as DNJ HCl, identifies a salt form of the molecule. The salt name is not a statement about botanical origin or clinical performance.

For purchasing and formulation calculations, ask whether the reported content refers to the hydrochloride salt or to DNJ equivalents. Also confirm whether the result is a quantitative assay or a chromatographic purity percentage. A clear analytical basis makes comparisons between suppliers more useful and reduces avoidable dose-calculation errors.

The mechanism centers on intestinal carbohydrate digestion

Some dietary carbohydrates need enzymatic digestion before their constituent sugars can be absorbed. DNJ has been investigated for inhibition of intestinal alpha-glucosidase activities, including enzymes involved in the final stages of carbohydrate breakdown.

In a 2021 enzyme study, DNJ showed strong inhibition of glucoamylase, sucrase, and isomaltase under the conditions tested, while its alpha-amylase inhibition was weak. These distinctions matter: an ingredient should not be described as blocking every carbohydrate through the same pathway. [1]

The practical formulation question is whether the ingredient becomes available at the relevant intestinal site while the meal is being digested. A larger plasma exposure is a different endpoint. It should not automatically be treated as evidence of a better meal-time formulation. This is a development implication of the mechanism, rather than a proven ranking of delivery technologies.

What the human studies actually tested

A 2017 randomized, double-blind crossover trial studied a proprietary standardized mulberry leaf extract in 37 adults with normal blood glucose. Participants consumed the extract with a 50 g maltodextrin challenge. The 250 mg and 500 mg extract conditions produced lower glucose incremental areas under the curve than placebo; the 125 mg condition did not show a statistically significant difference. [2]

A separate 2021 randomized crossover study tested 250 mg of a standardized mulberry leaf extract together with 75 g sucrose. The report analyzed complete glucose and insulin data for 36 participants. Glucose iAUC was approximately 42% lower and insulin iAUC approximately 40% lower than the sucrose-only condition in that specific acute test. [3]

These studies provide useful context for DNJ-containing ingredients, but the numbers belong to the tested extracts and study conditions. They are not performance claims for every DNJ HCl raw material, nor do they establish a universal serving size. Both studies involved proprietary extract formulations and disclosed links to the developer; independent replication remains useful. Short meal-challenge results also do not establish long-term weight loss or disease outcomes.

Match the ingredient form to the development brief

A standardized extract may suit a project that specifically values a botanical ingredient and has evidence relevant to that extract. A purified material gives the development team a different specification to evaluate, with clearer emphasis on identity, assay, impurities, and dose accounting. Greater purity alone does not prove greater clinical benefit.

For a DNJ HCl project, begin with the intended market, product category, target users, and formulation format. Then check whether the available evidence and safety documentation apply to that identity and intended use. Plant history, an extract study, and a salt-form specification answer different questions.

Formulation testing should follow the intended use

Capsules call for attention to blend uniformity, unit-to-unit content, and disintegration. Powder formats require checks on mixing, dose distribution, sensory properties, and compatibility with carriers. A beverage or gummy concept adds questions about pH, processing temperature, moisture, and storage.

These are testing priorities, not confirmation that every format is suitable. An attractive clear solution on the day of mixing is not a finished-product stability study. A useful development record follows the actual processing conditions and measures content, relevant impurities, physical changes, and packaging performance over time.

Release testing should also reflect the meal-time concept. Compare the proposed dosage form under relevant conditions before choosing immediate or modified release. If a formulation changes substantially from the material used in a human study, assess what additional evidence is needed to support the intended claims.

Build tolerability and documentation into the project

The two acute extract trials above reported favorable short-term tolerability under their test conditions. Those observations should remain tied to the tested material, participants, exposure, and duration. They do not establish universal tolerability or the long-term safety of a different purified salt formulation. 

For a US project, ingredient status and claim substantiation are separate reviews. FDA describes specific requirements for dietary supplement structure/function claims and a notification process for new dietary ingredients. Applicability must be assessed for the actual ingredient and intended use; a product listing or high-purity specification does not settle those questions. [4]

FTC guidance also requires health-related advertising claims to have appropriate scientific support. The evidence should match what customers will reasonably understand from the wording and context. An extract study should therefore be identified as such when discussed alongside a DNJ HCl product. [5,6]

What to request from a DNJ HCl supplier

Start with the current specification and a representative batch COA, then clarify the analytical method, reporting basis, relevant impurity limits, and storage instructions. Ask which safety and regulatory documents are available for the specific material and proposed use.

For sampling, define acceptance criteria before testing. Record the batch number, target concentration or serving size, formulation conditions, and the method used to recover and measure DNJ. A supplier comparison is more meaningful when all samples are assessed against the same requirements.

Commercial discussions should include the requested quantity, packaging, destination, required documentation, and timing. This gives the supplier a clear basis for a quotation and helps both teams identify technical questions before a pilot batch.

Discuss your DNJ ingredient project with UUBiotech

UUBiotech lists 1-deoxynojirimycin hydrochloride, CAS 73285-50-4, in its ingredient portfolio. Visit the product page for the current listed specification and contact the team to confirm the applicable grade, documentation, sample availability, and quotation conditions. 

When contacting us, include your company, target market, product category, dosage form, proposed DNJ content, and estimated purchase quantity. These details help us focus the discussion on the material and support your development team actually needs.

References

[1] Qiao Y, et al. Inhibitory effect of Morus australis leaf extract and its component iminosugars on intestinal carbohydrate-digesting enzymes. J Biosci Bioeng. 2021;132:226–233. 

[2] Lown M, et al. Mulberry extract and glucose tolerance in normoglycaemic adults. PLoS ONE. 2017;12:e0172239.

[3] Thondre PS, et al. Mulberry leaf extract and responses to sucrose in healthy subjects. Nutr Metab. 2021;18:41. Corrected reference information in 2021.

[4] FDA. Structure/Function Claims.

[5] FTC. Health Products Compliance Guidance.

[6] Youyou Biotechnology. 1-Deoxynojirimycin Hydrochloride product information. Supplier specifications, not clinical evidence.